Narjust Duma, MD, has been named associate director of the Cancer Care Equity Program and assistant professor of medicine at Dana-Farber Cancer Institute/Harvard Medical School. She will develop strategies to […] Read more
Gemcitabine: A New Chemotherapy Partner for Immune Checkpoint Inhibitors? Insights From the ORIENT-12 Study
Chunxia SuSquamous cell lung cancer (SqCLC), which accounts for approximately 25% to 30% of all lung cancer cases, is the second-most prevalent histologic subtype of NSCLC. Its distinct clinicopathologic and molecular […] Read more
Peter Bach, MD, is the new chief medical officer at Delfi Diagnostics, a developer of blood tests for early detection of multiple types of cancer. Dr. Bach leaves Memorial Sloan […] Read more
Joshua Bauml, MD, moves to The Janssen Pharmaceutical Companies of Johnson & Johnson
Joshua Bauml, MD, has moved to The Janssen Pharmaceutical Companies of Johnson & Johnson from the University of Pennsylvania. Dr. Bauml was with the University of Pennsylvania for a decade—2 […] Read more
Jean-Charles Soria, MD, PhD, joined Amgen in early August 2021 as senior vice president of the oncology therapeutic sector. Prof. Soria, previously served as senior vice president of Research & […] Read more
Suresh S. Ramalingam, MD, Appointed Executive Director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University
Suresh S. Ramalingam, MD, was appointed as the executive director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University on […] Read more
Telehealth Struggles to Find Permanent Footing After Rapid Growth During Pandemic
Beth Fand IncollingoThe ILCN is aware that the situation with telehealth differs across regions and that lack of access to technology is a huge obstacle. We would love to hear from IASLC members around the globe about your experiences. Please email us at [email protected]. Read more
Therapeutic Vaccine Development in Lung Cancer: Update and Recent Advances
Mohamad Omar Ashi+more
Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 […] Read more
Radiotherapy Inaccessibility in Lung Cancer Care: An Ongoing Crisis
Federico Maldonado Magos+more
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly […] Read more
Economics of Locally Advanced Lung Cancer Before and During COVID-19 Pandemic: A Perspective for Developing Countries
Andrés F. Cardona+more
Since December 2019, the world has been mired in a pandemic that has displaced other 21st-century health priorities for many populations. The social significance and speed of contagion from COVID-19 […] Read more